Exploring the Applications of Recombinant Viral Proteins and cDNA.

Products

Recombinant Viral Proteins and cDNA

Recombinant viral proteins and cDNA are two powerful tools in molecular biology and biotechnology that have numerous applications in research and medicine.

Recombinant viral proteins are artificially produced proteins that are derived from viruses. They are created by inserting the DNA sequence that codes for the desired viral protein into a host cell, such as bacteria or yeast. The host cell then produces the protein, which can be used for a variety of purposes, including as research tools or as components of vaccines.

cDNA, or complementary DNA, is a synthesized copy of the messenger RNA (mRNA) molecule that carries the genetic information from a gene. It is used to produce a corresponding DNA sequence, which can be inserted into a host organism, such as bacteria or yeast, to produce a desired protein. This is particularly useful when the original gene is difficult to isolate or express in its natural form.

The combination of recombinant viral proteins and cDNA can be used to create recombinant viral proteins with specific modifications or mutations. This allows researchers to study the effects of specific changes in the viral proteins, which can lead to a better understanding of how viruses function and how they can be targeted for therapeutic purposes.

Recombinant viral proteins and cDNA are also used in the development of vaccines. By producing recombinant viral proteins, researchers can create vaccines that stimulate the immune system to produce an immune response against the virus. This can be particularly useful for viruses that are difficult to grow in the laboratory or that do not produce a strong immune response.

In the field of molecular biology and biotechnology, recombinant viral proteins and cDNA have become highly valued tools due to their diverse applications in research and medicine. They enable scientists to manipulate and analyze modified viral proteins and develop vaccines for protection against viral infections. As research progresses, these tools will remain crucial in advancing our understanding of viruses and developing new treatments for viral diseases.

The use of recombinant proteins and cDNA has grown significantly in both academic research and therapeutic applications. However, successful expression of recombinant proteins in heterologous systems depends on several factors such as codon preference, RNA secondary structure, and GC content. Optimizing these factors can increase expression levels by up to a hundred times compared to pre-optimization. Bioclone has developed a proprietary technology platform that has yielded over 6,000 artificially synthesized codon-optimized cDNA clones, ready for producing recombinant proteins, and cloned in E.coli expression Vector.

Bioclone provides a range of recombinant antigens and codon-optimized cDNA that originate from hundreds of various viruses.

cDNA and recombinant antigen

Codon-optimized cDNA is cloned into E.coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
Recombinant protein applications: Western Blot may be used for other applications determined by the user.
Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions
Protein Activity: N/A
Protein Tag: Contains A 6x histidine tag
Protein Formulation: Liquid
Source: Produced from E.coli